Related Experiment Video
Updated: Jan 13, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Effect of therapeutic plasma exchange on the anti-factor Xa activity of enoxaparin: A case report
Thaddaus Hellwig1, Bri Jansma Vant Hul1, Michaela Schaar2
1South Dakota State University College of Pharmacy and Allied Health Professions, Sanford USD Medical Center, Sioux Falls, SD, USA.
Purpose:
A case is reported in which the anti-factor Xa activity of enoxaparin was measured during therapeutic plasma exchange (TPE).
Summary:
A 52-year-old male underwent TPE for antineutrophil cytoplasmic antibody-associated vasculitis while receiving therapeutic enoxaparin. Enoxaparin anti-factor Xa levels were measured before and immediately after TPE sessions as well as outside TPE sessions. The calculated enoxaparin half-life during TPE was 0.897 hours, whereas the calculated half-life outside TPE was 5.26 hours, demonstrating that the half-life of enoxaparin is dramatically shortened during TPE.
Conclusion:
Enoxaparin's anti-factor Xa activity should be monitored and dosing schedules should be adjusted to ensure therapeutic enoxaparin levels in all patients receiving TPE.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

